Abstract
PurposeNucleolar spindle-associated protein (NuSAP1) is an important mitosis-related protein, and aberrant NuSAP1 expression is associated with abnormal spindles and mitosis. This study investigated the prognostic value of NuSAP1 in breast cancer.MethodsTwo sets of tissue microarrays (TMAs) that included samples from 450 breast cancer patients were constructed, of which 250 patients were training set and the other 200 patients were validation set. Immunohistochemical staining was performed to determine the NuSAP1 levels. A Kaplan-Meier analysis was used to estimate the prognostic value of NuSAP1 in breast cancer. A stepwise Cox analysis was performed to construct a risk-prediction model for triple-negative breast cancer (TNBC). All statistical analysis was performed with SPSS software.ResultsThere were 108 (43.5%) and 88 (44.0%) patients expressed NuSAP1 in the training set and validation set respectively. High levels of NuSAP1 expression were related to poor disease-free survival (DFS) in both training (P = 0.028) and validation (P = 0.006) cohorts, particularly in TNBC. With combination of two cohorts, both NuSAP1 (HR = 4.136, 95% CI: 1.956–8.747, P < 0.001) and BRCA1 (HR = 0.383, 95% CI: 0.160–0.915, P = 0.031) were independent prognostic indicators of DFS in TNBC. A receiver operating characteristic (ROC) analysis revealed that the combination of NuSAP1 and BRCA1 significantly improved the prognostic power compared with the traditional model (0.778 versus 0.612, P < 0.001).ConclusionsOur study confirms the prognostic value of NuSAP1 in breast cancer. The combination of NuSAP1 and BRCA1 could improve the DFS prediction accuracy in TNBC.
Highlights
Breast cancer is the most common type of cancer in women worldwide, and approximately 1.2 million new cases and 465,000 deaths occur each year[1, 2]
Our study confirms the prognostic value of NuSAP1 in breast cancer
Increasing amounts of evidence indicate that cancers are often heterogeneous and that the response to treatment depends on the subtype of breast cancer[3, 4]
Summary
Breast cancer is the most common type of cancer in women worldwide, and approximately 1.2 million new cases and 465,000 deaths occur each year[1, 2]. Diagnosis and timely treatment are the most effective strategies for fighting breast cancer. An effective marker for breast cancer diagnosis or prognosis has not yet been identified. Increasing amounts of evidence indicate that cancers are often heterogeneous and that the response to treatment depends on the subtype of breast cancer[3, 4]. The androgen receptor (AR) has been identified as a new marker of a specific subtype of TNBC[8,9,10]. Additional efforts should be expanded to identify new indicators of breast cancer prognosis, especially for TNBC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
